Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Spotlight DK |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.
The Board of Directors of Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS), today announces the outcome of the rights issue of shares that the Board of Directors resolved to carry out on 24 April 2025 (the "Rights Issue").
The outcome indicates that the Rights Issue has been subscribed to approximately 42.4 percent with and without exercise of subscription rights, of which approximately 41.5 percent were subscribed for by exercise of subscription rights and approximately 0.9 percent were subscribed for without exercise of subscription rights. The outcome thus indicates that approximately an additional 4.6 percent will be subscribed for by guarantors. Based on the outcome, Curasight will receive approximately DKK 47 million from the Rights Issue before issue costs and repayment of bridge loan to Fenja Capital II A/S.
Ulrich Krasilnikoff, CEO Curasight, comments
"I am very pleased that despite the very challenging market conditions, we have been able to raise important new capital for the company. This allows us to continue on our mission to develop uTRACE® and uTREAT® in parallel and bring much needed new options to cancer patients. We are also thrilled to welcome two new strategic shareholders to Curasight, Curium and Pentwater. We can now focus on upcoming key clinical milestones for the company in the coming months, including the finalization of our Phase II study with uTRACE® in prostate cancer, with topline results expected in the second half of 2025. Additionally, we expect to initiate a Phase I study with uTREAT® in aggressive brain cancer, with preliminary efficacy data expected by the end of second half of 2025 and final efficacy data during the first half of 2026. I would like to take this opportunity to sincerely thank all our shareholders and partners for their continued trust and support as we work toward delivering innovative theranostic solutions for patients worldwide."
Outcome
The subscription period in the Rights Issue was concluded on 16 May 2025. The Rights Issue comprised a maximum of 50,522,324 shares, of which 23,737,362 shares were subscribed for, corresponding to approximately 47.0 percent of the total offering. Of these, 20,967,302 shares were subscribed for through the exercise of subscription rights, corresponding to approximately 41.5 percent. An additional 458,660 shares were subscribed for without the exercise of subscription rights, corresponding to approximately 0.9 percent. As the Rights Issue was subscribed below the guaranteed level, guarantors will subscribe for 2,311,400 shares, corresponding to approximately 4.6 percent, thereby bringing the total subscription up to the secured level of approximately 47.0 percent.
Allotment of shares subscribed for without exercise of subscription rights
The allotment of shares subscribed for without subscription rights has been carried out in accordance with the principles outlined in the information document prepared in connection with the Rights Issue and published on 29 April 2025. Notification of such allotment will be provided separately via a settlement note. Payment for subscribed and allotted shares shall be made through cash payment in accordance with the instructions specified in the settlement note. Nominee-registered shareholders will receive information regarding the allotment in accordance with the procedures established by their respective nominees.
Compensation for guarantee commitments
In connection with the Rights Issue, a number of external investors have entered into guarantee commitments. These commitments consist of a so-called bottom guarantee totaling approximately DKK 19.3 million. Under the terms of the guarantee agreements, the guarantors are entitled to receive compensation either in cash, equivalent to 13.0 percent of the guarantee amount, or in the form of newly issued shares corresponding to 22.0 percent of the guarantee amount. Compensation in the form of shares is intended to be settled through a directed share issue. The subscription price in such a directed share issue will correspond to the subscription price in the Rights Issue, which is DKK 1.98.
Changes in number of shares and share capital
Following the completion of the Rights Issue, the total number of ordinary shares in the Company will increase by 23,737,362, resulting in an increase in the total number of outstanding shares from 21,148,880 to 44,886,242. Consequently, the Company's share capital will increase by DKK 1,186,868.10, from DKK 1,057,444.00 to DKK 2,244,312.10. This corresponds to a dilution of approximately 52.9 percent of the total number of shares in the Company post-transaction.
Prior to the Rights Issue, Ulrich Krasilnikoff through UK Curacap Aps, Krasilnikoff A/S and Krasilnikoff Holding 1 ApS owned 4,081,777 shares, corresponding to approximately 19.3 percent of the Company. Following the Rights Issue, Ulrich Krasilnikoff owns 5,379,156 shares, equivalent to approximately 12.0 percent of the Company. Prior to the Rights Issue, Andreas Kjær through AK Holding 2014 ApS owned 6,059,040 shares, corresponding to approximately 28.6 percent of the Company. Following the transaction, Andreas Kjær owns 7,321,666 shares, equivalent to approximately 16.3 percent of the Company. Before the Rights Issue, Curium International Trading B.V. ("Curium") did not own any shares in the Company. Following the Rights Issue Curium will own 8,989,898 shares, corresponding to approximately 20.0 percent of the Company. Before the Rights Issue, Pentwater Capital Management Europe LLP. ("Pentwater") did not own any shares in the Company. Following the Rights Issue Pentwater will own 2,373,737 shares, corresponding to approximately 5.3 percent of the Company.
Interim shares
There will be no trading in the interim shares. The estimated date for conversion to ordinary shares is 10 June 2025.
Advisors
Sedermera Corporate Finance AB acts as Sole Global Coordinator and bookrunner in connection with the Rights Issue. DLA Piper is the Company's legal advisor. Danske Bank A/S is the settlement agent.